

ORAL PRESENTATION

Open Access

Cancer therapy by resuscitating Notch immune surveillance

Anil Shanker^{1,2*}, Duafalia F Dudimah¹, Samuel T Pellom Jr.^{1,3}, Roman V Uzhachenko¹, David P Carbone⁴, Mikhail M Dikov⁴

From Updates on Immunotherapy of Cancer and Immunoscore Symposium, part of the Sidra Symposia Series, held in partnership with the Society for Immunotherapy of Cancer
Doha, Qatar. 22-23 January 2014

The immunosuppressive tumor microenvironment perturbs numerous immune regulatory networks and usurps host antitumor immunity. We discovered that tumor interferes with host hematopoietic Notch system in lung cancer patients [1]. The resultant decrease in immune Notch signaling could be a major causative link in the inadequate induction of antitumor immunity. Interestingly, administration of the novel Delta-like ligand 1 (DLL1) multivalent cluster [1] and the FDA-approved proteasome inhibitor drug bortezomib, which also sensitizes tumors to death signals [2,3], restored the tumor-induced decrease in immune Notch. Bortezomib increased the expression of Notch target genes *Hes1* and *Hey1* in thymus, lymph node, and spleen of tumor-bearing mice. Moreover, bortezomib administration decreased the proportion of regulatory T cells and enhanced antitumor T cell production of IFN- γ . Results indicate that bortezomib-induced activation of Notch target genes *Hes1* and *Hey1* is through its inhibition of NF- κ B while its activation of *Deltex1* is mediated via PI3K. The potential of modulating antitumor Notch signaling by the prototypic DLL1 cluster in combination with bortezomib presents exciting opportunities to uncover multi-pronged immune stimulatory regimens. Therapeutic restoration of immune Notch signaling by bortezomib could provide effective treatment and recurrence-free survival in cancer patients by breaking tumor resistance, enhancing immune surveillance, and sustaining robust anti-tumor immunity.

Authors' details

¹Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN, USA. ²Host-Tumor Interactions Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University, Nashville, TN, USA. ³School of Graduate Studies and Research, Meharry Medical College, Nashville, TN, USA. ⁴Department of Medicine, James Cancer Center, The Ohio State University, Columbus, OH, USA.

Published: 24 February 2014

References

1. Huang Y, et al: Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. *Cancer Res* 2011, **71**(19):6122-31.
2. Jazirehi AR, Economou JS: Proteasome inhibition blocks NF- κ B and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. *Mol Cancer Ther* 2012, **11**(6):1332-41.
3. Shanker A, et al: Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. *J Natl Cancer Inst* 2008, **100**(9):649-62.

doi:10.1186/2051-1426-2-S1-O1

Cite this article as: Shanker et al.: Cancer therapy by resuscitating Notch immune surveillance. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 1):O1.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN, USA
Full list of author information is available at the end of the article